These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37961728)

  • 1. Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer.
    Cheng KH; Tu HP; Cheng KC; Scherrer-Crosbie M; Hsu TY
    medRxiv; 2023 Oct; ():. PubMed ID: 37961728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
    Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH
    Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
    Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation.
    Takahashi M; Okawa K; Morimoto T; Tsushima R; Sudo Y; Sakamoto A; Sogo M; Ozaki M; Doi M; Morita H; Okumura K; Ito H
    Age Ageing; 2022 Jul; 51(7):. PubMed ID: 35776672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
    Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
    Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease.
    Hsu CC; Chen CC; Chou CY; Chen KH; Wang SF; Chang SL; Chang YL
    J Thromb Thrombolysis; 2023 Nov; 56(4):518-528. PubMed ID: 37452906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
    Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Oct; 8(7):730-738. PubMed ID: 34694379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
    Nielsen PB; Søgaard M; Jensen M; Ording AG; Lip GY
    Int J Stroke; 2022 Jun; 17(5):536-544. PubMed ID: 34142600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.